Havrdova E, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials. EAN 2017, PR1092.
Dabrafenib plus trametinib bij BRAFV600E-gemuteerd laag- en hooggradig glioom
feb 2022 | Neuro-oncologie